We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
  • Login
  • Register
  • Newsfeed
  • GTDT
  • Hubs
  • Learn
  • Webinars
  • Store
  • Blog
  • Events
  • Popular
  • Awards
  • About
  • Compare
  • Topics
Getting The Deal Through joins Lexology
GTDT and Lexology Navigator have merged

CONTENT DEVELOPMENT

Become your target audience’s go-to resource for today’s hottest topics.

  • Trending Topics New
  • Discover Content
  • Horizons Beta
  • Ideation

CLIENT INTELLIGENCE

Understand your clients’ strategies and the most pressing issues they are facing.

  • Track Sectors
  • Track Clients
  • Mandates New
  • Discover Companies
  • Insight Reports

COMPETITOR INTELLIGENCE

Keep a step ahead of your key competitors and benchmark against them.

  • Benchmarking
  • Competitor Mandates Coming soon
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact customerservices@lexology.com

Register

PhRMA revises Code on Interactions with Healthcare Professionals

McDermott Will & Emery

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

USA July 15 2008

On July 10, 2008, the Board of Directors of the Pharmaceutical Research and Manufacturers Association of America (“PhRMA”) adopted revisions to the 2002 PhRMA Code on Interactions with Healthcare Professionals (the “2008 Code”).

Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • USA
  • Healthcare & Life Sciences
  • McDermott Will & Emery

Tagged with

  • Board of directors
  • Pharmaceutical Research and Manufacturers of America

Popular articles from this firm

  1. HHS Proposes Substantial Changes to the Stark Law and the Anti-Kickback Statute Regulations *
  2. A Tale of Two (or 33) Copyrights: Calculating Statutory Damages *
  3. Third Circuit Perpetuates Tuomey’s Controversial Stark Law “Volume or Value” Standard *
  4. Is Your Software a Medical Device? FDA Issues Six Digital Health Guidance Documents *
  5. Global Employment Contracts: The Modern Tower of Babel *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email enquiries@lexology.com.

Powered by Lexology

Featured Video

Jodi L. Avergun
1:47 min

Jodi L. Avergun

Cadwalader Wickersham & Taft LLP

Cannabis banking in the US
Watch now

Related topic hubs

  1. USA
  2. Healthcare & Life Sciences

Related USA articles

  1. PhRMA Code revisions adopted *
  2. PhRMA issues revised Code on Interactions with Healthcare Professionals *
  3. Revised PhRMA Code differs from device industry guidance *

Related international articles

  1. Pharmaceutical trade group reports 241 blood cancer drugs in development * - Global
  2. Global marketing practices: increased scrutiny ahead? * - Global
  3. EFPIA launches new clinical trial data portal gateway * - European Union
Gee Yung Loong
Senior Director
McAfee Inc
What our clients say

"I think it is a great service, continue the good work."

Back to Top
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • GDPR compliance
  • RSS feeds
  • Contact
  • Submissions
  • About
  • Login
  • Register
  • Follow on Twitter
  • Search
Law Business Research

© Copyright 2006 - 2019 Law Business Research